Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of telitacicept injection in primary IgA nephropathy
CTR20232735Phase 3Completed
- Sponsor
- RemeGen
- Start
- Jun 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in IgA nephropathy (IgAN), sponsored by RemeGen. Started Jun 2023; status: completed.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20232735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232735.